CAT-4001

CAT-4001 is a small molecule drug that consists of monomethyl fumarate covalently conjugated to docosahexaenoic acid (DHA). It is designed to modulate two key pathways simultaneously: activating Nuclear factor erythroid 2-related factor 2 (Nrf2) to reduce oxidative stress and inhibiting Nuclear factor NF-kappa-B (NF-κB) to reduce inflammation. The drug was developed by Catabasis Pharmaceuticals (which later became Astria Therapeutics) for the treatment of neurodegenerative diseases, particularly Friedreich's ataxia and amyotrophic lateral sclerosis (ALS). The mechanism aims to address the underlying problems of these diseases by reducing inflammation and oxidative stress while restoring mitochondrial function. Preclinical studies in cell cultures and animal models have shown CAT-4001 to be more effective than either of its components used individually or in combination with other therapies[1][2].